Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Genetic modification of primary human B cells to model high-grade lymphoma.

Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ.

Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x.

2.

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills RK, Russell NH, Osborne CS, Papaemmanuil E, Gottgens B, Campbell PJ, Huntly BJP.

Blood. 2019 Sep 12. pii: blood.2019001553. doi: 10.1182/blood.2019001553. [Epub ahead of print]

PMID:
31515253
3.

Kinase Networks Regulate Metabolism: I'D(H1) Never Have Guessed!

Horton S, Huntly BJP.

Cancer Discov. 2019 Jun;9(6):699-701. doi: 10.1158/2159-8290.CD-19-0373.

PMID:
31160331
4.

Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.

Lu Y, Stuart JH, Talbot-Cooper C, Agrawal-Singh S, Huntly B, Smid AI, Snowden JS, Dupont L, Smith GL.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11997-12006. doi: 10.1073/pnas.1816399116. Epub 2019 May 24.

5.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP.

J Exp Med. 2019 Apr 1;216(4):966-981. doi: 10.1084/jem.20181276. Epub 2019 Mar 19.

6.

Histone modifiers are oxygen sensors.

Gallipoli P, Huntly BJP.

Science. 2019 Mar 15;363(6432):1148-1149. doi: 10.1126/science.aaw8373. No abstract available.

PMID:
30872506
7.

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS.

Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.

8.

Prognostic Models Turn the Heat(IT)up on FLT3ITD -Mutated AML.

Gallipoli P, Huntly BJP.

Clin Cancer Res. 2019 Jan 15;25(2):460-462. doi: 10.1158/1078-0432.CCR-18-3146. Epub 2018 Nov 2.

9.

Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML.

Giotopoulos G, Huntly BJP.

Cancer Cell. 2018 Oct 8;34(4):533-535. doi: 10.1016/j.ccell.2018.09.004.

10.

Population dynamics of normal human blood inferred from somatic mutations.

Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I, Anderson E, O'Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ.

Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0. Epub 2018 Sep 5.

11.

Hematopoietic stem cells made BETter by inhibition.

Marando L, Huntly BJP.

Haematologica. 2018 Jun;103(6):919-921. doi: 10.3324/haematol.2018.193706. No abstract available.

12.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

13.

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP.

Blood. 2018 Apr 12;131(15):1639-1653. doi: 10.1182/blood-2017-12-820035. Epub 2018 Feb 20.

14.

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.

Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ.

Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.

15.

Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP.

Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21.

16.

Novel epigenetic therapies in hematological malignancies: Current status and beyond.

Gallipoli P, Huntly BJP.

Semin Cancer Biol. 2018 Aug;51:198-210. doi: 10.1016/j.semcancer.2017.07.005. Epub 2017 Aug 4. Review.

PMID:
28782607
17.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
18.

Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Dec 1;540(7631):150. doi: 10.1038/nature20144. Epub 2016 Oct 19. No abstract available.

PMID:
27760119
19.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

20.

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.

Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T.

Leukemia. 2017 Apr;31(4):934-944. doi: 10.1038/leu.2016.280. Epub 2016 Oct 14.

21.

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Aug 31;537(7621):544-547. doi: 10.1038/nature19353. Erratum in: Nature. 2016 Dec 1;540(7631):150.

22.

Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.

Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SEW, Huntly BJ, Ottersbach K.

Cell Rep. 2016 Jul 26;16(4):1039-1054. doi: 10.1016/j.celrep.2016.06.046. Epub 2016 Jul 7.

23.

Independence of epigenetic and genetic diversity in AML.

Sasca D, Huntly BJ.

Nat Med. 2016 Jul 7;22(7):708-9. doi: 10.1038/nm.4136. No abstract available.

PMID:
27387883
24.

Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA.

Nat Struct Mol Biol. 2016 Jul;23(7):673-81. doi: 10.1038/nsmb.3249. Epub 2016 Jun 13.

PMID:
27294782
25.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

Blood. 2016 Jul 7;128(1):e1-9. doi: 10.1182/blood-2015-11-683334. Epub 2016 Apr 27.

26.

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Grimwade D, Ivey A, Huntly BJ.

Blood. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496. Epub 2015 Dec 10. Review.

27.

BET inhibitor resistance emerges from leukaemia stem cells.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA.

Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888. Epub 2015 Sep 14.

28.

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ.

J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661. Epub 2015 Aug 24.

29.

Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.

van der Weyden L, Giotopoulos G, Wong K, Rust AG, Robles-Espinoza CD, Osaki H, Huntly BJ, Adams DJ.

BMC Cancer. 2015 Aug 13;15:585. doi: 10.1186/s12885-015-1586-1.

30.

BET bromodomain inhibitors in leukemia.

Basheer F, Huntly BJ.

Exp Hematol. 2015 Aug;43(8):718-31. doi: 10.1016/j.exphem.2015.06.004. Epub 2015 Jul 9. Review.

PMID:
26163798
31.

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.

Gallipoli P, Giotopoulos G, Huntly BJ.

Ther Adv Hematol. 2015 Jun;6(3):103-19. doi: 10.1177/2040620715577614. Review.

32.

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ.

Oncogene. 2016 Jan 21;35(3):279-89. doi: 10.1038/onc.2015.92. Epub 2015 Apr 20.

33.

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL.

Stem Cells. 2014 Sep;32(9):2324-37. doi: 10.1002/stem.1748.

34.

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.

Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24.

35.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

36.

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ.

Leukemia. 2014 Feb;28(2):311-20. doi: 10.1038/leu.2013.338. Epub 2013 Nov 13.

37.

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.

Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA, Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T.

Leukemia. 2014 Jan;28(1):88-97. doi: 10.1038/leu.2013.234. Epub 2013 Aug 9.

PMID:
23929215
38.

Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations.

Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P.

Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113. Epub 2013 Jun 6.

39.

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.

Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B.

Oncogene. 2013 Nov 28;32(48):5471-80. doi: 10.1038/onc.2013.175. Epub 2013 May 27.

40.

Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.

Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS.

Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117. Epub 2013 Apr 18.

41.

An unexpected finding after a fall from a horse.

Raby S, Greaves D, Padayatty J, Huntly B.

BMJ. 2013 Feb 12;346:f724. doi: 10.1136/bmj.f724. No abstract available.

PMID:
23403830
42.

Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.

Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE.

Blood. 2013 Mar 21;121(12):2289-300. doi: 10.1182/blood-2012-07-446120. Epub 2013 Jan 17. Erratum in: Blood. 2014 May 1;123(18):2901.

PMID:
23327922
43.

Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.

PMID:
23051844
44.

Disordered signaling in myeloproliferative neoplasms.

Anand S, Huntly BJ.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1017-35. doi: 10.1016/j.hoc.2012.07.004. Epub 2012 Aug 25. Review.

PMID:
23009935
45.

Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry.

Grimwade L, Gudgin E, Bloxham D, Bottley G, Vassiliou G, Huntly B, Scott MA, Erber WN.

Cytometry A. 2012 Oct;81(10):896-900. doi: 10.1002/cyto.a.22116. Epub 2012 Sep 11.

46.

Targeting epigenetic readers in cancer.

Dawson MA, Kouzarides T, Huntly BJ.

N Engl J Med. 2012 Aug 16;367(7):647-57. doi: 10.1056/NEJMra1112635. Review. No abstract available.

PMID:
22894577
47.

Recent advances in acute myeloid leukemia stem cell biology.

Horton SJ, Huntly BJ.

Haematologica. 2012 Jul;97(7):966-74. doi: 10.3324/haematol.2011.054734. Epub 2012 Apr 17. Review.

48.

The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.

Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A, Göttgens B, Van Deursen JM, Huntly BJ.

Mol Cell Biol. 2011 Dec;31(24):5046-60. doi: 10.1128/MCB.05830-11. Epub 2011 Oct 17.

49.

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T.

Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.

50.

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.

Mduff FK, Hook CE, Tooze RM, Huntly BJ, Pandolfi PP, Turner SD.

Lab Invest. 2011 Sep;91(9):1298-303. doi: 10.1038/labinvest.2011.96. Epub 2011 Jun 27.

Supplemental Content

Loading ...
Support Center